MX2023013173A - Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos. - Google Patents

Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos.

Info

Publication number
MX2023013173A
MX2023013173A MX2023013173A MX2023013173A MX2023013173A MX 2023013173 A MX2023013173 A MX 2023013173A MX 2023013173 A MX2023013173 A MX 2023013173A MX 2023013173 A MX2023013173 A MX 2023013173A MX 2023013173 A MX2023013173 A MX 2023013173A
Authority
MX
Mexico
Prior art keywords
degraders
cdk2
compositions
methods
same
Prior art date
Application number
MX2023013173A
Other languages
English (en)
Inventor
Robert Aversa
Yi Zhang
Xiaozhang Zheng
Philip Collier
Xiao Zhu
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of MX2023013173A publication Critical patent/MX2023013173A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Vending Machines For Individual Products (AREA)

Abstract

La presente invención proporciona compuestos, composiciones de ellos, y métodos de uso de los mismos.
MX2023013173A 2021-05-07 2022-05-06 Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos. MX2023013173A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163185929P 2021-05-07 2021-05-07
PCT/US2022/028076 WO2022236058A1 (en) 2021-05-07 2022-05-06 Cdk2 degraders and uses thereof

Publications (1)

Publication Number Publication Date
MX2023013173A true MX2023013173A (es) 2023-11-30

Family

ID=83932976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013173A MX2023013173A (es) 2021-05-07 2022-05-06 Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos.

Country Status (14)

Country Link
US (1) US12097261B2 (es)
EP (1) EP4334307A1 (es)
JP (1) JP2024519215A (es)
KR (1) KR20240020735A (es)
CN (1) CN117715904A (es)
AR (1) AR125798A1 (es)
AU (1) AU2022271290A1 (es)
BR (1) BR112023023223A2 (es)
CA (1) CA3217792A1 (es)
CO (1) CO2023014770A2 (es)
IL (1) IL308314A (es)
MX (1) MX2023013173A (es)
TW (1) TW202309030A (es)
WO (1) WO2022236058A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4334307A1 (en) 2021-05-07 2024-03-13 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
WO2023220640A1 (en) * 2022-05-10 2023-11-16 Biotheryx, Inc. Cdk protein degraders, pharmaceutical compositions, and therapeutic applications
WO2023239629A1 (en) * 2022-06-06 2023-12-14 Plexium, Inc. Compounds and pharmaceutical compositions that degrade cdk2
WO2024173766A1 (en) * 2023-02-17 2024-08-22 Differentiated Therapeutics, Inc. Cyclin dependent kinase degraders and methods of use thereof
WO2024182555A1 (en) * 2023-02-28 2024-09-06 Differentiated Therapeutics, Inc. Cyclin dependent kinase degraders and methods of use thereof

Family Cites Families (497)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323469A (en) 1980-10-28 1982-04-06 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Process for O-acylating phenol derivatives and acylating compositions for this purpose
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5360811A (en) 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
JP3545461B2 (ja) 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
WO1996007655A1 (fr) 1994-09-06 1996-03-14 Banyu Pharmaceutical Co., Ltd. Nouveau derive de carbapenem
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
WO1999062503A2 (en) 1998-05-29 1999-12-09 Cnrs (Centre National De Recherche Scientifique) France Innovation Scientifique Et Transfert Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
JP2002523501A (ja) 1998-09-01 2002-07-30 エルジ ケミカル リミテッド フラボン構造を有する新規なｃｄｋ阻害剤
WO2000035908A1 (en) 1998-12-17 2000-06-22 F. Hoffmann-La Roche Ag 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
PT1149106E (pt) 1998-12-17 2003-06-30 Hoffmann La Roche 4,5-azolo-oxindois
KR20000055080A (ko) 1999-02-03 2000-09-05 성재갑 싸이클린 의존 키나아제 저해제 및 그의 제조 방법
KR100368515B1 (ko) 1999-02-03 2003-01-24 주식회사 엘지생명과학 싸이클린 의존 키나아제 저해제 및 그의 제조 방법
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
US6440959B1 (en) 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
DE19936789A1 (de) 1999-08-09 2001-03-01 Vectron Therapeutics Ag Neue Pyrrolidinole und ihre Verwendung für die Tumortherapie
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GEP20053479B (en) 1999-12-10 2005-03-25 Pfizer Prod Inc Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
DE10002509A1 (de) 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
JP2003525296A (ja) 2000-02-28 2003-08-26 スージェン・インコーポレーテッド キナーゼ阻害剤としての３−（ピロリルラクトン）−２−インドリノン化合物
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
CA2414468A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
AP2001002266A0 (en) 2000-08-31 2001-09-30 Pfizer Prod Inc Pyrazole derivatives.
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1322750A4 (en) 2000-09-08 2004-09-29 California Inst Of Techn PROTEOLYSIC CHIMERAL PHARMACEUTICAL
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US6504034B2 (en) 2001-01-23 2003-01-07 Hoffmann-La Roche Inc. Naphthostyrils
GB0107901D0 (en) 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
ATE350376T1 (de) 2001-04-27 2007-01-15 Zenyaku Kogyo Kk Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
EP1256578B1 (en) 2001-05-11 2006-01-11 Pfizer Products Inc. Thiazole derivatives and their use as cdk inhibitors
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PL374023A1 (en) 2002-05-30 2005-09-19 Vertex Pharmaceuticals Incorporated Inhibitors of jak and cdk2 protein kinases
EP1536827B1 (en) 2002-08-14 2009-01-07 Silence Therapeutics Aktiengesellschaft Use of protein kinase n beta
NZ539165A (en) 2002-09-04 2008-03-28 Schering Corp Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
AU2003287178A1 (en) 2002-10-10 2004-05-04 Smithkline Beecham Corporation Chemical compounds
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
FR2847253B1 (fr) 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
ATE410415T1 (de) 2003-02-27 2008-10-15 Smithkline Beecham Corp Neue verbindungen
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
BRPI0410870A (pt) 2003-05-30 2006-07-04 Gemin X Biotechnologies Inc compostos trieterocìclicos, composições, e métodos para tratar cáncer ou doenças virais
EP1644003A1 (en) 2003-06-04 2006-04-12 Vernalis (Cambridge) Limited Triazolo ´1,5-a!pyrimidines and their use in medicine
CA2531069A1 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
CN1826120A (zh) 2003-07-23 2006-08-30 幸讬制药公司 用于发炎与免疫相关用途的化合物
JP4398263B2 (ja) 2004-01-13 2010-01-13 富士通株式会社 経路設計方法
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
WO2005082903A1 (en) 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
AU2005245875C1 (en) 2004-05-13 2017-08-31 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
EP1598348A1 (en) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
KR100858262B1 (ko) 2004-10-13 2008-09-11 에프. 호프만-라 로슈 아게 Ｃｄｋ2 및 혈관신생에 대한 저해제로서 유용하고, 유방암,대장암, 폐암 및 전립선암의 치료용으로 유용한이중치환된 피라졸로벤조디아제핀
CN100569773C (zh) 2004-10-14 2009-12-16 霍夫曼-拉罗奇有限公司 作为抗癌剂的新型吖吲哚噻唑啉酮
BRPI0517426A (pt) 2004-12-17 2008-10-07 Astrazeneca Ab composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente
DK1856135T3 (da) 2005-01-19 2010-04-12 Rigel Pharmaceuticals Inc Prodrugs af 2,4-pyrimidindiamin-forbindelser og deres anvendelser
AR052660A1 (es) 2005-01-21 2007-03-28 Astex Therapeutics Ltd Derivados de pirazol para inhibir la cdk's y gsk's
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
WO2006105386A1 (en) 2005-03-30 2006-10-05 Genentech, Inc. Cdk2 inhibitors
CN101928264B (zh) 2005-05-12 2012-03-28 雅培制药有限公司 细胞凋亡促进剂
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
RS54271B1 (en) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
JP5270353B2 (ja) 2005-10-07 2013-08-21 エクセリクシス， インク． ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法
HUE028987T2 (en) 2005-11-01 2017-01-30 Targegen Inc BI-aryl-meta-pyrimidine inhibitors of kinases
US7705009B2 (en) 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
RS55576B1 (sr) 2005-12-13 2017-05-31 Incyte Holdings Corp Heteroaril supstituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
CN102690221B (zh) 2005-12-23 2014-12-03 西兰岛药物有限公司 改性的拟赖氨酸化合物
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
ATE471940T1 (de) 2006-04-26 2010-07-15 Hoffmann La Roche Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor
TW200811169A (en) 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
ITTO20060575A1 (it) 2006-08-02 2008-02-03 Univ Pisa Inibitori di zinco proteinasi tioaril sostituiti e loro usi
PL2526934T4 (pl) 2006-09-22 2016-09-30 Inhibitory kinazy tyrozynowej Brutona
CA2672518A1 (en) 2006-12-22 2008-07-03 Novartis Ag Organic compounds and their uses
US20100279316A1 (en) 2007-01-19 2010-11-04 Leonid Gorelik Antibodies to Phosphorylated IRAK4
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
GB0706632D0 (en) 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
JP5932217B2 (ja) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009062112A2 (en) 2007-11-09 2009-05-14 The Salk Institute For Biological Studies Use of tam receptor inhibitors as antimicrobials
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
ES2602577T3 (es) 2008-03-11 2017-02-21 Incyte Holdings Corporation Derivados de azetidina y ciclobutano como inhibidores de JAK
JP2011518841A (ja) 2008-04-24 2011-06-30 ニューリンク ジェネティクス， インコーポレイテッド Ｉｄｏ阻害剤
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
HRP20240240T1 (hr) 2008-12-09 2024-04-26 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
US8921037B2 (en) 2008-12-16 2014-12-30 Bo Han PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
LT3023438T (lt) 2009-09-03 2020-05-11 Merck Sharp & Dohme Corp. Anti-gitr antikūnai
JP2012254939A (ja) 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
ES2557454T3 (es) 2009-12-10 2016-01-26 F. Hoffmann-La Roche Ag Anticuerpos que se unen al dominio extracelular 4 de CSF1R humana y su utilización
WO2011109400A2 (en) 2010-03-04 2011-09-09 Macrogenics,Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
MX336682B (es) 2010-03-05 2016-01-27 Hoffmann La Roche Anticuerpos contra csf-1r humanos y usos de los mismos.
WO2011107553A1 (en) 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
US8114621B2 (en) 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
TR201900368T4 (tr) 2010-05-04 2019-02-21 Five Prime Therapeutics Inc Csf1r'ye bağlanan antikorlar.
EP2588129A4 (en) 2010-06-30 2014-07-09 Univ Brandeis ON SMALL MOLECULES TARGETED PROTEIN REMOVAL
KR20190077610A (ko) 2010-07-13 2019-07-03 에프. 호프만-라 로슈 아게 Irak4 조절제로서 피라졸로[1,5a]피리미딘 및 티에노[3,2b]피리미딘 유도체
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
EP3357915A1 (en) 2010-11-19 2018-08-08 Ligand Pharmaceuticals Inc. Heterocycle amines with anti-inflammatory activity
EP2649099A4 (en) 2010-12-07 2016-10-19 Univ Yale HYDROPHOBIC MARKING OF SMALL MOLECULES OF FUSION PROTEINS AND INDUCED DEGRADATION THEREOF
LT2649086T (lt) 2010-12-09 2017-11-10 The Trustees Of The University Of Pennsylvania Chimeriniu antigenų receptoriumi modifikuotų ląstelių naudojimas vėžio gydymui
AU2011347711B2 (en) 2010-12-20 2017-02-02 Merck Serono S.A. Indazolyl triazole derivatives as IRAK inhibitors
EP2663312B1 (en) 2011-01-10 2017-10-11 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2012129258A1 (en) 2011-03-22 2012-09-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
NO2694640T3 (es) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
WO2013066729A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
CA2856895C (en) 2011-11-28 2021-10-26 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2013087699A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
AU2013207972B2 (en) 2012-01-10 2017-06-15 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
EP2802608A4 (en) 2012-01-12 2015-08-05 Univ Yale COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY E3 UBIQUITIN LIGASE
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
ES2686500T3 (es) 2012-01-13 2018-10-18 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas
CN104254533B (zh) 2012-01-13 2017-09-08 百时美施贵宝公司 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
CN104093740B (zh) 2012-02-06 2018-01-09 弗·哈夫曼-拉罗切有限公司 使用csf1r抑制剂的组合物和方法
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20220162819A (ko) 2012-05-11 2022-12-08 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
ES2589558T3 (es) 2012-07-10 2016-11-15 Ares Trading S.A. Derivados de pirimidin pirazolilo
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014011906A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
BR112015002285B1 (pt) 2012-08-09 2022-05-10 Celgene Corporation Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer
EP3679949A1 (en) 2012-08-31 2020-07-15 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
BR112015004547A8 (pt) 2012-09-19 2018-01-23 Hoffmann La Roche compostos, composição farmacêutica, uso de um composto e método para o tratamento ou melhoria do cãncer
WO2014058685A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP2903613B1 (en) 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of irak4 activity
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
BR112015009850A2 (pt) 2012-11-08 2017-07-11 Bristol Myers Squibb Co compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
GB201311910D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
AU2014214321B2 (en) 2013-02-07 2018-04-19 Merck Patent Gmbh Pyridazinone-amides derivatives
LT2953952T (lt) 2013-02-07 2017-08-25 Merck Patent Gmbh Makrocikliniai piridazinono dariniai
EP2970334B1 (en) 2013-03-15 2018-05-23 Biogen MA Inc. Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases
JP2016531870A (ja) 2013-09-27 2016-10-13 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
CA2929316C (en) 2013-11-08 2021-12-28 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders
US10053431B2 (en) 2013-11-18 2018-08-21 Hoffmann-La Roche Inc. Tetrahydro-benzodiazepinones
KR102398473B1 (ko) 2013-11-27 2022-05-16 시그널켐 라이프사이언시즈 코포레이션 Tam 패밀리 키나제 억제제로서의 아미노피리딘 유도체
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
UY35935A (es) 2014-01-03 2015-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
CA2935880A1 (en) 2014-01-10 2015-07-16 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
EA031913B1 (ru) 2014-01-13 2019-03-29 Ориджин Дискавери Текнолоджиз Лимитед Бициклические гетероциклические производные в качестве ингибиторов irak4
SG11201606080SA (en) 2014-02-03 2016-08-30 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2935071A1 (en) 2014-03-17 2015-09-24 F. Hoffmann-La Roche Ag Piperidine-dione derivatives
NZ724578A (en) 2014-04-04 2019-05-31 Pfizer Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
EP3131588A4 (en) 2014-04-14 2018-01-10 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
KR20160145803A (ko) 2014-04-22 2016-12-20 님버스 아이리스 인코포레이티드 Irak 억제제 및 이의 용도
CN104003988A (zh) 2014-06-05 2014-08-27 中国药科大学 基于3-氨基-β-咔啉及其衍生物的CDK2激酶抑制剂及其制备方法和用途
EA201692418A1 (ru) 2014-06-20 2017-04-28 Ауриджен Дискавери Текнолоджиз Лимитед Замещенные индазольные соединения в качестве irak4 ингибиторов
US10092555B2 (en) 2014-06-27 2018-10-09 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
TW201613872A (en) 2014-07-18 2016-04-16 Biogen Ma Inc IRAK4 inhibiting agents
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
EP3200790B1 (en) 2014-09-30 2020-08-26 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
US9926330B2 (en) 2014-09-30 2018-03-27 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
US9969749B2 (en) 2014-09-30 2018-05-15 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
WO2016053772A1 (en) 2014-09-30 2016-04-07 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
CN105878244A (zh) 2014-11-12 2016-08-24 中国药科大学 Cdk2抑制剂及其用途
LT3221306T (lt) 2014-11-20 2020-03-10 Merck Patent Gmbh Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas
CN107257800B (zh) 2014-12-23 2020-06-30 达纳-法伯癌症研究所股份有限公司 通过双功能分子诱导靶蛋白降解的方法
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CN104606197A (zh) 2014-12-31 2015-05-13 芜湖杨燕制药有限公司 一种化合物的抗肿瘤用途
KR20220029783A (ko) 2015-01-20 2022-03-08 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2016144849A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of irak4 activity
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
EP3268004B1 (en) 2015-03-12 2019-12-18 Merck Sharp & Dohme Corp. Pyrrolopyridazine inhibitors of irak4 activity
US10329295B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrrolotriazine inhibitors of IRAK4 activity
US10329294B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of IRAK4 activity
WO2016149668A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2016172560A1 (en) 2015-04-22 2016-10-27 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
CZ307147B6 (cs) 2015-05-14 2018-02-07 Ústav experimentální botaniky AV ČR, v. v. i. 5-Substituované 7-[4-(2-pyridyl)fenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako léčiva, a farmaceutické přípravky
WO2016197032A1 (en) 2015-06-04 2016-12-08 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
EP3313840B1 (en) 2015-06-24 2019-07-24 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
CN105085620B (zh) 2015-06-25 2018-05-08 中山大学附属第一医院 一种靶向泛素化降解Smad3的化合物
WO2017004133A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
BR112017028394A2 (pt) 2015-07-10 2018-08-28 Arvinas Inc composto, composição, e, métodos para induzir a degradação de uma proteína-alvo em uma célula e para tratar um estado doente ou uma condição doente.
MX2018000471A (es) 2015-07-13 2018-04-10 Arvinas Inc Moduladores de proteolisis basados en alanina y metodos de uso asociados.
JP6802251B2 (ja) 2015-07-14 2020-12-16 ミッション セラピューティクス リミティド 癌の処置のためのｄｕｂ阻害剤としてのシアノピロリジン
CN108026065A (zh) 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的吲唑及氮杂吲唑化合物
CN108024971A (zh) 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的取代的氮杂化合物
EP3331905B1 (en) 2015-08-06 2022-10-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CA2996389C (en) 2015-08-27 2020-04-07 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators
ES2911888T3 (es) 2015-09-18 2022-05-23 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de IRAK y usos de los mismos
CN108290879B (zh) 2015-09-18 2022-01-11 默克专利有限公司 用作irak抑制剂的杂芳基化合物及其用途
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
US9938264B2 (en) 2015-11-02 2018-04-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
WO2017108723A2 (en) 2015-12-22 2017-06-29 F. Hoffmann-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
US20190016703A1 (en) 2015-12-30 2019-01-17 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
WO2017117473A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional molescules for her3 degradation and methods of use
US11427561B2 (en) 2016-01-20 2022-08-30 Biogen Ma Inc. IRAK4 inhibiting agents
CA3017740A1 (en) 2016-03-16 2017-09-21 Pearlie BURNETTE Small molecules against cereblon to enhance effector t cell function
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
US11192898B2 (en) 2016-04-06 2021-12-07 The Regents Of The University Of Michigan MDM2 protein degraders
WO2017176958A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
US20190054097A1 (en) 2016-04-21 2019-02-21 Bioventures, Llc Compositions targeting senescent cells and the uses thereof
CA3018991A1 (en) 2016-04-21 2017-10-26 Bioventures, Llc Compounds that induce degradation of anti-apoptotic bcl-2 family proteins and the uses thereof
AU2017254711B2 (en) 2016-04-22 2021-01-21 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017201069A1 (en) 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
KR101825065B1 (ko) 2016-05-24 2018-02-05 한국화학연구원 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017207385A1 (de) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2018005356A1 (en) 2016-06-27 2018-01-04 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
BR112019002610A2 (pt) 2016-08-15 2019-07-02 Pfizer piridopirimidinonas inibidoras de cdk2/4/6
JP2019196309A (ja) 2016-09-15 2019-11-14 武田薬品工業株式会社 複素環化合物
KR20190055260A (ko) 2016-10-11 2019-05-22 아비나스 인코포레이티드 안드로겐 수용체의 표적 분해용 화합물 및 방법
WO2018089736A1 (en) 2016-11-10 2018-05-17 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
JP7308146B2 (ja) 2016-11-22 2023-07-13 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド インターロイキン１受容体関連キナーゼの阻害剤およびその使用
KR20190093205A (ko) 2016-12-21 2019-08-08 바이오테릭스, 인코포레이티드 단백질 표적화에 사용하기 위한 티에노피롤 유도체, 조성물, 방법 및 이의 용도
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Servalon ligands and bifunctional compounds containing them
CA3053006C (en) 2017-02-08 2023-09-05 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
AU2018265130B2 (en) 2017-05-11 2022-03-24 Bristol-Myers Squibb Company Thienopyridines and benzothiophenes useful as IRAK4 inhibitors
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
CN109422733A (zh) 2017-09-03 2019-03-05 上海美志医药科技有限公司 一类抑制并降解酪氨酸蛋白激酶alk的化合物
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
US11623932B2 (en) 2017-09-22 2023-04-11 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
CN107987054B (zh) 2017-11-28 2020-05-19 四川大学 一种cdk2抑制剂
CN107903256B (zh) 2017-11-29 2019-11-15 南方医科大学 一种含取代噻唑的2,4-二氨基嘧啶及其应用
WO2019113071A1 (en) 2017-12-05 2019-06-13 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating alk-mediated cancer
JP7565078B2 (ja) 2017-12-13 2024-10-10 上海科技大学 Ａｌｋタンパク質分解剤及びそれらの癌療法における使用
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc IRAK joints and used in them
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CA3090417A1 (en) 2018-02-23 2019-08-29 Dana-Farber Cancer Institute, Inc. Small molecules for inducing selective protein degradation and uses thereof
CN108484606B (zh) 2018-03-16 2020-03-06 江南大学 一种嘧啶并[4,5-f]喹唑啉类化合物及其应用
CA3096790C (en) 2018-04-09 2024-03-19 Shanghaitech University Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
MX2020010571A (es) 2018-04-13 2021-01-08 Arvinas Operations Inc Ligandos de cereblon y compuestos bifuncionales que los comprenden.
CN108484613B (zh) 2018-05-22 2020-07-07 江南大学 一种吡唑并[1,5-a]嘧啶类化合物及其应用
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
WO2020006264A1 (en) 2018-06-29 2020-01-02 Dana-Farber Cancer Institute, Inc. Ligands to cereblon (crbn)
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
CN110684015A (zh) 2018-07-06 2020-01-14 四川大学 靶向alk的protac及其应用
WO2020010210A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
AU2019307631A1 (en) 2018-07-20 2020-12-17 Dana-Farber Cancer Institute, Inc. Degraders that target proteins via KEAP1
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
CN110835345A (zh) 2018-08-17 2020-02-25 中国科学院上海药物研究所 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
US20210315904A1 (en) 2018-08-22 2021-10-14 Newave Pharmaceutical Inc. Bcl-2 inhibitors
AU2019348006A1 (en) 2018-09-27 2021-02-18 Dana-Farber Cancer Institute, Inc. Degraders that target Alk and therapeutic uses thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
MX2021006154A (es) 2018-11-30 2021-08-24 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
WO2020142228A1 (en) 2019-01-03 2020-07-09 The Regents Of The University Of Michigan Androgen receptor protein degraders
KR20210121186A (ko) * 2019-01-31 2021-10-07 화이자 인코포레이티드 Cdk2에 대한 억제 활성을 갖는 3-카본일아미노-5-사이클로펜틸-1h-피라졸 화합물
US20220143195A1 (en) 2019-02-13 2022-05-12 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
JP2022519772A (ja) 2019-02-15 2022-03-24 インサイト・コーポレイション サイクリン依存性キナーゼ２バイオマーカー及びその使用
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
KR20220004978A (ko) 2019-03-28 2022-01-12 에싸 파마 아이엔씨. 단백질 분해 표적 키메라 리간드로서 사용하기 위한 안드로겐 수용체 조절제 및 방법
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020206034A1 (en) 2019-04-01 2020-10-08 G1 Therapeutics, Inc. Cell cycle inhibiting compounds for the treatment of medical disorders
US20230093099A1 (en) 2019-04-02 2023-03-23 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
AU2020256220A1 (en) 2019-04-04 2021-09-16 Dana-Farber Cancer Institute, Inc. CDK2/5 degraders and uses thereof
CN113939300A (zh) 2019-04-05 2022-01-14 凯麦拉医疗公司 Stat降解剂和其用途
WO2020210229A1 (en) 2019-04-08 2020-10-15 Dana-Farber Cancer Institute, Inc. Degraders of kelch-like ech-associated protein 1 (keap1)
JP2022527216A (ja) 2019-04-12 2022-05-31 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓ及びＡｉｏｌｏｓの三環式分解誘導薬
AU2020263390A1 (en) 2019-04-23 2021-10-07 Dana-Farber Cancer Institute, Inc. Degraders of cyclin-dependent kinase 12 (CDK12) and uses thereof
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
CN110204543B (zh) 2019-06-27 2022-03-29 江苏省中医药研究院 一种基于Cereblon配体诱导BET降解的吡咯并吡啶酮类双功能分子化合物
AU2020302118A1 (en) 2019-06-28 2022-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN110256465B (zh) 2019-07-13 2021-08-13 南方医科大学 一种含二氢吡喃并噻唑的2,4-二氨基嘧啶及其应用
US20220281831A1 (en) 2019-07-15 2022-09-08 Kymera Therapeutics, Inc. Fused-glutarimide crbn ligands and uses thereof
WO2021016521A1 (en) 2019-07-25 2021-01-28 Beth Israel Deaconess Medical Center, Inc. Photo induced control of protein destruction
WO2021018018A1 (en) 2019-07-26 2021-02-04 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use
US20220289711A1 (en) 2019-07-31 2022-09-15 Foghorn Therapeutics Inc. Compounds and uses thereof
JP2022543231A (ja) 2019-08-05 2022-10-11 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の分解誘導剤およびその使用
PE20221010A1 (es) 2019-08-14 2022-06-15 Incyte Corp Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
WO2021058017A1 (en) 2019-09-29 2021-04-01 Beigene, Ltd. Degradation of androgen receptor (ar) by conjugation of ar antagonists with e3 ligase ligand and methods of use
US20220372042A1 (en) 2019-10-03 2022-11-24 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114502555B (zh) 2019-10-15 2024-07-16 常州千红生化制药股份有限公司 用于治疗增殖性疾病和疾患的4-(咪唑并[1,2-a]吡啶-3-基)-N-(吡啶-3-基)嘧啶-2-胺的衍生物
US20240190861A1 (en) 2019-10-17 2024-06-13 Cisen Pharmaceutical Co., Ltd Aminopyrimidine compound as cdk2/4/6 triple inhibitor
IL293797A (en) 2019-12-04 2022-08-01 Nurix Therapeutics Inc Bifunctional compounds for btk degradation via the ubiquitin proteosome pathway
WO2021129653A1 (zh) 2019-12-23 2021-07-01 上海济煜医药科技有限公司 一种蛋白降解剂化合物的制备方法和应用
EP4110340A4 (en) 2020-02-25 2024-08-28 Dana Farber Cancer Inst Inc POTENT AND SELECTIVE ALK DEGRADING AGENTS
CA3173262A1 (en) 2020-02-26 2021-09-02 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (trk) degradation compounds and methods of use
JP7549032B2 (ja) 2020-03-13 2024-09-10 プロセネスター エルエルシー ＣＤＫ阻害剤としてのピリド［２，３－ｄ］ピリミジン－７（８Ｈ）－オン
CN113387931A (zh) 2020-03-13 2021-09-14 四川海思科制药有限公司 一种具有抑制或降解蛋白激酶的化合物及其制备方法和药学上的应用
US20230158152A1 (en) 2020-03-17 2023-05-25 Medshine Discovery Inc. Proteolysis regulator and method for using same
CN111285851A (zh) 2020-03-23 2020-06-16 沈阳药科大学 靶向降解黏着斑激酶的化合物及其在医药上的应用
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
CN113509557A (zh) 2020-04-09 2021-10-19 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
JPWO2021210343A1 (es) 2020-04-16 2021-10-21
CN113527329A (zh) 2020-04-22 2021-10-22 上海中医药大学附属龙华医院 含硒化合物及其医药用途
WO2021216828A1 (en) 2020-04-24 2021-10-28 Massachusetts Institute Of Technology Chimeric degraders of cyclin-dependent kinase 9 and uses thereof
CA3172498A1 (en) 2020-04-30 2021-11-04 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
WO2021228814A1 (en) 2020-05-15 2021-11-18 ETH Zürich Mdm2 inhibitor response prediction method
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
CN113698391B (zh) 2020-05-21 2023-06-06 上海拓界生物医药科技有限公司 4-氨基嘧啶或2-氨基三嗪类化合物及其制备方法
CN113773315A (zh) 2020-06-10 2021-12-10 无锡佰翱得生物科学有限公司 细胞周期蛋白依赖性激酶2（cdk2）高选择性氘代抑制剂
TWI781651B (zh) 2020-06-12 2022-10-21 大陸商上海濟煜醫藥科技有限公司 酞嗪酮類化合物及其製備方法和醫藥用途
US20230226195A1 (en) 2020-06-17 2023-07-20 Dana-Farber Cancer Institute, Inc. Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an e3-ligase system
CN115702155A (zh) 2020-06-17 2023-02-14 微境生物医药科技(上海)有限公司 新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物
CN117327059A (zh) 2020-07-08 2024-01-02 北京泰德制药股份有限公司 抑制并诱导蛋白降解的化合物
WO2022015670A1 (en) 2020-07-14 2022-01-20 Nikang Therapeutics, Inc. Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
WO2022012623A1 (en) 2020-07-16 2022-01-20 Beigene, Ltd. Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
CN111777604B (zh) 2020-07-17 2021-12-21 常州大学 一种作为cdk2抑制剂的2-胺基噻唑嘧啶的合成方法
US20230321042A1 (en) 2020-07-20 2023-10-12 Pfizer Inc. Combination therapy
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
KR20230050375A (ko) 2020-08-05 2023-04-14 상하이 리딩택 파마슈티컬 코., 엘티디. 단백질 표적화 및 분해용 화합물, 이의 제조방법 및 용도
CN115942937A (zh) 2020-08-17 2023-04-07 南京明德新药研发有限公司 嘧啶并环类化合物
WO2022051616A1 (en) 2020-09-03 2022-03-10 Board Of Regents Of The University Of Nebraska Cdk targeted heterobifunctional small molecule proteolysis targeting chimeras
CN114163444B (zh) 2020-09-11 2023-07-14 江苏恒瑞医药股份有限公司 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
US11744896B2 (en) 2020-09-28 2023-09-05 Creighton University Compositions, use, and method for CDK2-PROTACs for cancer therapy and hearing loss
CN116323570A (zh) 2020-09-30 2023-06-23 上海睿跃生物科技有限公司 治疗疾病的化合物和方法
EP4225749A1 (en) 2020-10-07 2023-08-16 Cullgen (Shanghai), Inc. Compounds and methods of treating cancers
IL302037A (en) 2020-10-14 2023-06-01 C4 Therapeutics Inc Tricyclic heterobifunctional compounds for degradation of targeted proteins
CN114349738B (zh) 2020-10-14 2023-05-05 清华大学 一类靶向降解cdk2的小分子缀合物及其应用
AU2021361043A1 (en) 2020-10-14 2023-06-08 C4 Therapeutics, Inc. Tricyclic ligands for degradation of ikzf2 or ikzf4
AU2021372427A1 (en) 2020-10-26 2023-06-08 Dana-Farber Cancer Institute, Inc. Compounds for targeted protein degradation of kinases
JP2023548335A (ja) 2020-11-05 2023-11-16 クロノス バイオ インコーポレイテッド Ｃｄｋ９活性を調節するための化合物および方法
US20240059671A1 (en) 2020-11-12 2024-02-22 Cullgen (Shanghai), Inc. Tyrosine kinase 2 (tyk2) degradation compounds and methods of use
WO2022109307A1 (en) 2020-11-19 2022-05-27 Mei Pharma, Inc. Treatment of kras mutant cancers
JP2023550461A (ja) 2020-11-20 2023-12-01 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
WO2022111526A1 (zh) 2020-11-25 2022-06-02 四川海思科制药有限公司 一种苯环衍生物及其组合物和药学上的应用
WO2022111634A1 (zh) 2020-11-26 2022-06-02 成都赛璟生物医药科技有限公司 杂芳基并喹唑啉类化合物作为蛋白激酶抑制剂
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
JPWO2022113621A1 (es) 2020-11-27 2022-06-02
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
CN114591213A (zh) 2020-12-04 2022-06-07 华东师范大学 4-乙酰基-5-苯基吡咯烷-2,3-二酮类化合物及其在cdk2蛋白抑制剂中应用
KR20220085735A (ko) 2020-12-14 2022-06-22 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
AU2021401056A1 (en) 2020-12-20 2023-08-03 Guangzhou Lupeng Pharmaceutical Company Ltd. Btk degrader
CA3202355A1 (en) 2020-12-22 2022-06-30 Jiping Fu Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
WO2022135365A1 (en) 2020-12-22 2022-06-30 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Disubstituted cyclopentane kinase inhibitors
TW202229268A (zh) 2020-12-22 2022-08-01 大陸商上海拓界生物醫藥科技有限公司 Ｃｄｋ２抑制劑及其製備方法
US20240076287A1 (en) 2020-12-24 2024-03-07 Pfizer Inc. Solid forms of a cdk2 inhibitor
CN116981675A (zh) 2020-12-31 2023-10-31 百济神州有限公司 通过布鲁顿氏酪氨酸激酶（btk）抑制剂与e3连接酶配体的缀合降解btk和使用方法
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
US20240140952A1 (en) 2021-01-15 2024-05-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors and degraders of janus kinase 2
WO2022152259A1 (zh) 2021-01-15 2022-07-21 江苏先声药业有限公司 Cdk2/4/6抑制剂及其制备方法和应用
WO2022159650A1 (en) 2021-01-22 2022-07-28 Icahn School Of Medicine At Mount Sinai HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF eEF1A2
WO2022159644A1 (en) 2021-01-23 2022-07-28 Newave Pharmaceutical Inc. Spirocyclic mdm2 modulator and uses thereof
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
TW202239402A (zh) 2021-01-29 2022-10-16 美商賽迪拉治療股份有限公司 Ｃｄｋ２抑制劑及其使用方法
CN112898271B (zh) 2021-01-29 2022-03-25 中国医科大学 N-(吡啶-3-基)吡咯烷-2-甲酰胺类化合物及其制备方法和用途
WO2022165185A1 (en) 2021-02-01 2022-08-04 Beth Israel Deaconess Medical Center, Inc. Cancer-selective target degradation by targeting group caged protacs
CN116472270A (zh) 2021-02-05 2023-07-21 上海齐鲁制药研究中心有限公司 Cdk抑制剂
US20240165243A1 (en) 2021-02-10 2024-05-23 Beigene Switzerland Gmbh Egfr degraders and methods of use
US20240190855A1 (en) 2021-02-12 2024-06-13 Relay Therapeutics, Inc. Cdk inhibitors and methods of use thereof
US20240299344A1 (en) 2021-03-04 2024-09-12 Lifemine Therapeutics Compounds, compositions, and methods of treatment thereof
WO2022187693A1 (en) 2021-03-05 2022-09-09 Umbra Therapeutics Inc. Covalent cdk2-binding compounds for therapeutic purposes
TW202237597A (zh) 2021-03-19 2022-10-01 大陸商上海齊魯製藥研究中心有限公司 新型egfr降解劑
CA3211378A1 (en) 2021-03-29 2022-10-06 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicine
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
US20220340579A1 (en) 2021-04-12 2022-10-27 Incyte Corporation Pyrazolyl bicyclic amines as cdk2 inhibitors
MX2023012981A (es) 2021-05-03 2024-01-11 Nurix Therapeutics Inc Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
EP4334307A1 (en) 2021-05-07 2024-03-13 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
WO2022242725A1 (zh) 2021-05-19 2022-11-24 和径医药科技（上海）有限公司 一类新型蛋白降解剂及其应用
US20240261297A1 (en) 2021-05-20 2024-08-08 St. John's Cancer Institute Anti-cdk inhibitors for cancer treatment
US20240277852A1 (en) 2021-05-20 2024-08-22 Dana-Farber Cancer Institute, Inc. Inhibitors and degraders of pip4k protein
US20240343732A1 (en) 2021-05-28 2024-10-17 Qurient Co., Ltd. Compounds for degradation of cyclin-dependent kinase 7(cdk7)
CN113278010A (zh) 2021-06-01 2021-08-20 中国科学院上海有机化学研究所 一类蛋白激酶降解剂及其用途
WO2022258023A1 (zh) 2021-06-09 2022-12-15 郑州同源康医药有限公司 用作cdk激酶抑制剂的化合物及其应用
IL309013A (en) 2021-06-16 2024-01-01 Blueprint Medicines Corp Converted pyrimidinylpyrazoles as CDK2 inhibitors
JP2024522768A (ja) 2021-06-16 2024-06-21 バイオセリックス， インコーポレイテッド Ｓｏｓ１タンパク質分解剤、その医薬組成物及びそれらの治療的応用
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
EP4359403A1 (en) 2021-06-21 2024-05-01 BeiGene Switzerland GmbH (r) -glutarimide crbn ligands and methods of use
CN115304606B (zh) 2021-06-21 2024-04-19 清华大学 一种同时靶向btk和gspt1蛋白的降解剂
WO2022268229A1 (zh) 2021-06-25 2022-12-29 和径医药科技（上海）有限公司 蛋白抑制剂或降解剂、包含其的药物组合物及医药上的用途
WO2022272106A1 (en) 2021-06-26 2022-12-29 Cedilla Therapeutics, Inc. Cdk2 inhibitors and methods of using the same
US20240336643A1 (en) 2021-06-28 2024-10-10 Dana-Farber Cancer Institute, Inc. Bifunctional compounds that degrade alk and uses thereof
US11932648B2 (en) 2021-06-28 2024-03-19 Blueprint Medicines Corporation CDK2 inhibitors
WO2023274397A1 (zh) 2021-07-01 2023-01-05 上海拓界生物医药科技有限公司 Cdk2抑制剂及其制备方法和用途
WO2023281413A1 (en) 2021-07-09 2023-01-12 Pfizer Inc. Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
CA3217661A1 (en) 2021-07-16 2023-01-19 Alyssa VERANO Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
EP4378936A1 (en) 2021-07-30 2024-06-05 Hinova Pharmaceuticals Inc. Bifunctional chimeric heterocyclic compound and use thereof as androgen receptor degrader
US20240335452A1 (en) 2021-08-04 2024-10-10 Cullgen (Shanghai), Inc. Compositions and methods of combination therapy for targeting lymphoma
EP4382530A1 (en) 2021-08-04 2024-06-12 Beijing Tide Pharmaceutical Co., Ltd. Shp2 inhibitor, pharmaceutical composition comprising same, and application thereof
CN115703760B (zh) 2021-08-11 2024-05-31 山东大学 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用
WO2023023664A1 (en) 2021-08-19 2023-02-23 University Of Virginia Patent Foundation Sulfonyl-triazoles useful as covalent kinase ligands
WO2023023531A1 (en) 2021-08-20 2023-02-23 Biotheryx, Inc. Estrogen receptor degraders, pharmaceutical compositions, and therapeutic applications
WO2023023941A1 (en) 2021-08-24 2023-03-02 Biofront Ltd (Cayman) Hpk1 degraders, compositions comprising the hpki degrader, and methods of using the same
WO2023039405A1 (en) 2021-09-08 2023-03-16 The Curators Of The University Of Missouri Methods of using usp15 inhibitors
CN115806551A (zh) 2021-09-14 2023-03-17 优领医药科技(香港)有限公司 含吡唑多环类衍生物、其药学上可接受的盐及其制备方法和应用
WO2023051302A1 (zh) 2021-09-29 2023-04-06 中国医药研究开发中心有限公司 具有细胞周期蛋白依赖性激酶抑制活性的杂环化合物及其制备方法和医药用途
WO2023056423A1 (en) 2021-09-30 2023-04-06 Essa Pharma, Inc. Androgen receptor modulators and methods for use as bifunctional degraders
WO2023059609A1 (en) 2021-10-04 2023-04-13 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
KR20240077491A (ko) 2021-10-05 2024-05-31 제넨테크, 인크. 시클로펜틸피라졸 cdk2 억제제
TW202322799A (zh) 2021-10-06 2023-06-16 美商Ｃ４醫藥公司 冠狀病毒非結構性蛋白3降解化合物
JP2024537394A (ja) 2021-10-14 2024-10-10 クルゲン（シャンハイ），インク． 修飾タンパク質およびタンパク質分解剤
WO2023061478A1 (zh) 2021-10-15 2023-04-20 先声再明医药有限公司 三环类化合物
WO2023069700A1 (en) 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
WO2023069720A1 (en) 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
JP2024539269A (ja) 2021-10-22 2024-10-28 グルータクス セラピューティクス （シャンハイ） カンパニー、リミテッド Ｃｒｂｎ ｅ３リガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
AU2022378463A1 (en) 2021-10-25 2024-05-09 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
WO2023072096A1 (zh) 2021-10-25 2023-05-04 优领医药科技(香港)有限公司 含四氢呋喃多环类衍生物、其药学上可接受的盐及其制备方法和应用
WO2023080652A1 (en) 2021-11-02 2023-05-11 Autotac Inc. Androgen receptor degraders for the treatment of castration-resistant prostate cancer and use thereof
WO2023081759A1 (en) 2021-11-03 2023-05-11 Relay Therapeutics, Inc. Bifunctional pi3k-alpha inhibitors and uses thereof
TW202325280A (zh) 2021-11-09 2023-07-01 大陸商上海拓界生物醫藥科技有限公司 一種胺基吡唑衍生物及其製備方法和用途
CN115745979A (zh) 2021-11-11 2023-03-07 中国医学科学院医药生物技术研究所 一种蛋白靶向降解化合物及其用途
TW202329964A (zh) 2021-11-17 2023-08-01 大陸商浙江同源康醫藥股份有限公司 用於egfr蛋白降解的化合物及其用途
WO2023092088A1 (en) 2021-11-19 2023-05-25 Blueprint Medicines Corporation Cdk2 inhibitors and methods of making and using same
CN116143766A (zh) 2021-11-23 2023-05-23 四川海思科制药有限公司 Cdk2降解剂及其用途
EP4436970A1 (en) 2021-11-23 2024-10-02 Origenis GmbH Pyrazolotriazine derivatives useful as cdk9 inhibitors
CN118234726A (zh) 2021-11-25 2024-06-21 江苏恒瑞医药股份有限公司 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
EP4444724A1 (en) 2021-11-30 2024-10-16 BeiGene Switzerland GmbH Compounds for the degradation of egfr kinase
CN116217549A (zh) 2021-12-01 2023-06-06 嘉兴优博生物技术有限公司 靶向蛋白酶降解(ted)平台
WO2023100131A1 (en) 2021-12-02 2023-06-08 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
EP4440575A1 (en) 2021-12-02 2024-10-09 Pfizer Inc. Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
CN113999210B (zh) 2021-12-03 2023-05-23 郑州大学第一附属医院 一组2-苯氨基-4-三氮唑基嘧啶类衍生物及其应用
CN114262321B (zh) 2021-12-07 2024-08-09 中国药科大学 一种双稳态光调控小分子蛋白降解剂、制备方法及应用
US20230192706A1 (en) 2021-12-10 2023-06-22 Incyte Corporation Bicyclic amines as cdk2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4452415A1 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023116884A1 (en) 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2023129564A1 (en) 2021-12-27 2023-07-06 Cygnal Therapeutics, Inc. Degraders of grk2 and uses thereof
EP4457230A1 (en) 2021-12-30 2024-11-06 BeiGene Switzerland GmbH Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
AU2022424178A1 (en) 2021-12-30 2024-07-11 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
AU2023204747A1 (en) 2022-01-07 2024-06-27 Dana-Farber Cancer Institute, Inc. Targeting swi/snf related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (smarca4)
WO2023137225A1 (en) 2022-01-17 2023-07-20 Newave Pharmaceutical Inc. Btk degrader
WO2023141635A2 (en) 2022-01-21 2023-07-27 The Regents Of The University Of California Her3 ligands and uses thereof
CN114380822B (zh) 2022-01-25 2023-02-17 中国人民解放军北部战区总医院 β-咔波啉母核的CDKs抑制剂及其制备方法和抗肿瘤的应用
WO2023141852A1 (zh) 2022-01-27 2023-08-03 益方生物科技(上海)股份有限公司 Cdk2抑制剂及其制备方法和用途
CN118632848A (zh) 2022-01-29 2024-09-10 甘李药业股份有限公司 小脑蛋白e3泛素连接酶抑制剂
WO2023143482A1 (zh) 2022-01-29 2023-08-03 上海辉启生物医药科技有限公司 2-氨基嘧啶类化合物或其盐及其制备方法和用途
WO2023150612A1 (en) 2022-02-03 2023-08-10 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
WO2023154426A1 (en) 2022-02-11 2023-08-17 Relay Therapeutics, Inc. Cdk inhibitors and methods of use thereof
WO2023151635A1 (zh) 2022-02-14 2023-08-17 标新生物医药科技(上海)有限公司 基于喹唑啉取代戊二酰亚胺骨架的化合物及其应用
WO2023160572A1 (zh) 2022-02-24 2023-08-31 楚浦创制（武汉）医药科技有限公司 吡唑类衍生物、药物组合物及应用
WO2023164175A2 (en) 2022-02-25 2023-08-31 Tegid Therapeutics, Inc. Protacs of malt1
TW202342023A (zh) 2022-03-07 2023-11-01 美商英塞特公司 Ｃｄｋ２抑制劑之固體形式、鹽及製備方法
US20240018136A1 (en) 2022-03-09 2024-01-18 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
WO2023178130A1 (en) 2022-03-16 2023-09-21 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions, and therapeutic applications
AU2023233730A1 (en) 2022-03-17 2024-09-26 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230295118A1 (en) 2022-03-18 2023-09-21 EnhancedBio Inc. Compounds and methods for the targeted degradation of cyclin dependent kinases
US20230303509A1 (en) 2022-03-28 2023-09-28 Nikang Therapeutics, Inc. Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
WO2023192534A1 (en) 2022-03-30 2023-10-05 Ohio State Innovation Foundation Cyclin-dependent kinase 9 (cdk9) degraders and methods of using thereof
WO2023185920A1 (en) 2022-03-30 2023-10-05 Berrybio (Shanghai) Limited Fak degraders, pharmaceutical compositions, and therapeutic applications
CN117157298A (zh) 2022-03-31 2023-12-01 石药集团中奇制药技术（石家庄）有限公司 一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途
CN114685507B (zh) 2022-04-06 2024-01-12 山东大学 嘌呤胺衍生物类cdk2抑制剂及其制备方法和应用
TW202342038A (zh) 2022-04-15 2023-11-01 中國商北京泰德製藥股份有限公司 Egfr降解劑
US20240050577A1 (en) 2022-04-27 2024-02-15 Risen (Suzhou) Pharma Tech Co., Ltd. Cdk inhibitors and pharmaceutical uses thereof
WO2023220640A1 (en) 2022-05-10 2023-11-16 Biotheryx, Inc. Cdk protein degraders, pharmaceutical compositions, and therapeutic applications
CN114853672B (zh) 2022-05-12 2023-06-23 中国人民解放军北部战区总医院 作为CDKs抑制剂的他克林衍生物及其应用
CN117143093A (zh) 2022-05-24 2023-12-01 中国科学院上海药物研究所 一种蛋白降解剂及其制备方法和用途
WO2023226920A1 (en) 2022-05-27 2023-11-30 Anrui Biomedical Technology (Guangzhou) Co.,Ltd. Aminoheteroaryl kinase inhibitors
WO2023239629A1 (en) 2022-06-06 2023-12-14 Plexium, Inc. Compounds and pharmaceutical compositions that degrade cdk2
WO2023240024A1 (en) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
CN117229286A (zh) 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
WO2023244710A1 (en) 2022-06-16 2023-12-21 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof
WO2023249974A2 (en) 2022-06-20 2023-12-28 Incyclix Bio, Inc. Cyclin-dependent kinase 2 inhibitors for medical treatment
CN117263957A (zh) 2022-06-20 2023-12-22 中国科学院基础医学与肿瘤研究所(筹) 一种具有六并五芳杂环的环状小分子化合物及其应用
WO2023249970A1 (en) 2022-06-21 2023-12-28 Nikang Therapeutics, Inc. Bifunctional compounds containing pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2023249968A1 (en) 2022-06-22 2023-12-28 Nikang Therapeutics, Inc. Bifunctional compounds containing pyrido[2,3-djpyrimidin-7(8h)-one derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
US20240002339A1 (en) 2022-06-30 2024-01-04 Regents Of The University Of Minnesota Therapeutic compounds and methods
CN117384161A (zh) 2022-07-04 2024-01-12 华东理工大学 靶向降解cdk蛋白的化合物及其应用
CN115010711A (zh) 2022-07-12 2022-09-06 江南大学 一种蝶啶7（8h）-酮类化合物及其在药学上的应用
CN115160298B (zh) 2022-07-28 2023-05-23 中国人民解放军北部战区总医院 一种他克林-磺酰胺类衍生物及其制备方法与应用
CN115845068A (zh) 2022-08-17 2023-03-28 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） Tacc2抑制剂和cdk2抑制剂的组合物在制备预防或治疗肿瘤药物中的应用
WO2024039903A2 (en) 2022-08-19 2024-02-22 Kymera Therapeutics, Inc. Cdk2 inhibitors and uses thereof
WO2024039901A2 (en) 2022-08-19 2024-02-22 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
CN116283915A (zh) 2022-09-08 2023-06-23 中国科学院生物物理研究所 促进致癌融合蛋白EML4-ALK通过泛素化途径降解的小分子化合物dEALK1
CN115650968B (zh) 2022-12-27 2023-03-21 英矽智能科技(上海)有限公司 作为cdk选择性抑制剂的新型哒嗪酮化合物
CN116440139A (zh) 2023-01-09 2023-07-18 浙江大学杭州国际科创中心 一种降解剂组合及其应用
CN116554126A (zh) 2023-04-18 2023-08-08 兰州大学 一种靶向降解cdk6的化合物及应用
CN116675731A (zh) 2023-04-28 2023-09-01 浙江大学 靶向细胞周期蛋白依赖性激酶12/13的小分子缀合物及其应用
CN116813621A (zh) 2023-06-08 2023-09-29 江南大学 9h嘌呤类化合物及其药物组合物和用途

Also Published As

Publication number Publication date
CA3217792A1 (en) 2022-11-10
TW202309030A (zh) 2023-03-01
WO2022236058A1 (en) 2022-11-10
CO2023014770A2 (es) 2023-11-10
BR112023023223A2 (pt) 2024-01-30
CN117715904A (zh) 2024-03-15
US12097261B2 (en) 2024-09-24
JP2024519215A (ja) 2024-05-09
EP4334307A1 (en) 2024-03-13
KR20240020735A (ko) 2024-02-15
IL308314A (en) 2024-01-01
US20230110180A1 (en) 2023-04-13
AU2022271290A1 (en) 2023-11-23
AR125798A1 (es) 2023-08-16

Similar Documents

Publication Publication Date Title
MX2022007576A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021012216A (es) Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2023007852A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2023013173A (es) Degradadores de cinasa 2 dependiente de ciclina (cdk2) y sus usos.
ZA201906822B (en) Indole ahr inhibitors and uses thereof
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2020001103A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
WO2021127283A3 (en) Irak degraders and uses thereof
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2022011437A (es) Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
ZA202309446B (en) Rapamycin analogs and uses thereof
EP4112611A3 (en) Modulators of sestrin-gator2 interaction and uses thereof
MX2023006719A (es) Degradadores de cinasas asociadas con el receptor de interleucina 1 (irak) y sus usos.
MX2023011933A (es) Moduladores del linfoma de linaje b de casitas de ligasa e3 b (cbl-b) y usos de estos.
MX2023003973A (es) Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos.
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof